Edwards Lifesciences stock gains 1.26 percent near its yearly high
π Edwards Lifesciences stock gained 1.26 percent to close at USD 89.45 on September 22, 2026.
π° The company reported quarterly EPS of USD 0.78, beating the consensus estimate of USD 0.74.
π Year-over-year quarterly revenue growth reached 13.6 percent in the latest period cited.
π― MarketBeat lists a consensus price target of USD 100.27, implying potential upside from current levels.
π The stock trades at a P/E ratio of 50.70, which is above the market average of 39.07.
π Expected earnings growth for the coming year is projected at 13.00 percent.
Bullish Signals
- Edwards Lifesciences stock gained 1.26 percent to reach USD 89.45, trading near its yearly high of USD 96.29.
- The company beat quarterly EPS estimates with actual results of USD 0.78 versus a consensus of USD 0.74.
- Edwards Lifesciences achieved year-over-year quarterly revenue growth of 13.6 percent.
Risk Factors
- The stock trades at a price-to-earnings ratio of 50.70, which is significantly above the cited market average of about 39.07.
Full Analysis
Edwards Lifesciences stock rose 1.26 percent to close at USD 89.45 on September 22, 2026, trading near its yearly high of USD 96.29. The company reported quarterly earnings per share (EPS) of USD 0.78, beating the consensus estimate of USD 0.74 by USD 0.04. This positive performance contributed to a market capitalization of USD 50.80 billion as of September 21, 2026.
The stock traded within a 52-week range between USD 72.30 and USD 96.29, with daily volume reaching 866,356 shares. Analyst consensus price targets from MarketBeat stand at USD 100.27, suggesting potential upside of approximately 11 percent from the current quote. The target range spans from USD 85.00 to USD 110.00.
Financial metrics indicate Edwards Lifesciences is trading at a price-to-earnings ratio of 50.70, which is above the cited market average of about 39.07. Year-over-year quarterly revenue growth was reported at 13.6 percent, while expected earnings growth for the coming year is projected at 13.00 percent, rising from USD 3.00 to USD 3.39 per share.